<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="mdef-cmd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">mdef-cmd</book-part-id>
      <title-group>
        <title><italic toggle="yes">LAMA2</italic>-Related Muscular Dystrophy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Early-Onset Laminin Alpha 2 Deficiency, Laminin Alpha 2-Deficient Congenital Muscular Dystrophy, Late-Onset Laminin Alpha 2 Deficiency, MDC1A, Merosin-Deficient Congenital Muscular Dystrophy Type 1A</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quijano-Roy</surname>
            <given-names>Susana</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Centre de R&#x000e9;f&#x000e9;rence des Maladies Neuromusculaires (GNMH)<break/>Service de P&#x000e9;diatrie<break/>H&#x000f4;pital Raymond Poincar&#x000e9;<break/>Garches, France</aff>
          <email>susana.quijano-roy@rpc.aphp.fr</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sparks</surname>
            <given-names>Susan E</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Sanofi Genzyme<break/>Cambridge, Massachusetts</aff>
          <email>susan.sparks@genzyme.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rutkowski</surname>
            <given-names>Anne</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Cure CMD Chairman, Kaiser Permanente Southern California (SCPMG)<break/>Los Angeles, California</aff>
          <email>anne.rutkowski@curecmd.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>7</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="l1cam" document-type="chapter">L1 Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="chrom17-lis" document-type="chapter"><italic toggle="yes">LIS1</italic>-Associated Lissencephaly/Subcortical Band Heterotopia</related-object>
      <abstract id="mdef-cmd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The clinical manifestations of <italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD) range from severe, early-onset congenital muscular dystrophy (CMD) &#x02013; referred to as early-onset <italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD) in this <italic toggle="yes">GeneReview</italic> &#x02013; to mild, later childhood-onset limb-girdle type muscular dystrophy &#x02013; referred to here as late-onset <italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD). Children with early-onset <italic toggle="yes">LAMA2</italic> MD have profound hypotonia with muscle weakness evident at birth or within the first six months of life, poor spontaneous movements with contractures of the large joints, and weak cry often associated with respiratory failure. Feeding difficulties with failure to thrive, aspiration, and recurrent chest infections are typical. Progressive scoliosis starting in childhood is common. Seizures and, less often, cardiac involvement can occur. Typically, individuals with early-onset <italic toggle="yes">LAMA2</italic> MD do not achieve independent ambulation. Intellect is usually normal. Those with limb-girdle type muscular dystrophy have later onset of proximal muscle weakness and delayed motor milestones, but achieve independent ambulation; they may develop a rigid spine syndrome with joint contractures. Progressive respiratory insufficiency and scoliosis can occur.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis of <italic toggle="yes">LAMA2</italic> MD is based on: clinical findings; elevated serum CK concentration; specific abnormal white matter signal on T<sub>2</sub>-weighted MRI by age one year; complete or partial laminin &#x003b1;2 deficiency on immunohistochemical (IHC) staining of muscle and/or skin; and biallelic mutation of <italic toggle="yes">LAMA2</italic>, the gene encoding the laminin subunit alpha-2.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> For infants and children with early-onset <italic toggle="yes">LAMA2</italic> MD, multidisciplinary care may include: supplemental feeding and gastrostomy; cough assistance, followed by noninvasive ventilation support (intermittent positive pressure breathing [IPPB] or bilevel ventilation) for respiratory insufficiency; physical therapy and casts, splints, or orthotics for joint contractures; trunk orthotics or braces and spinal fusion as needed for scoliosis. Seizures are treated in a routine manner. Those with late-onset laminin &#x003b1;2 deficiency benefit from regular physical therapy to stretch the joints and spine and may need care for progressive respiratory insufficiency and joint and/or spinal deformities.</p>
          <p>
            <italic toggle="yes">Surveillance:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Early-onset <italic toggle="yes">LAMA2</italic> MD: During the first five years biannual follow up by: a dietician/gastroenterologist to assess nutritional intake and swallowing; a pulmonologist to assess respiratory function; a physical therapist to assess strength and joint range of motion; and an orthopedist to assess the spine. After age five years at least annual follow up is recommended if the disease course is stable. In the absence of cardiac symptoms, evaluation by a cardiologist including electrocardiogram and echocardiogram at age five years, ten years, and then every two years is recommended.</p>
            </list-item>
            <list-item>
              <p>Late-onset <italic toggle="yes">LAMA2</italic> MD: Follow up with a pulmonologist, cardiologist, and physical therapist.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> (1) Succinylcholine during induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities; (2) statin, cholesterol-lowering medication because of risk of muscle damage.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">LAMA2</italic>-related muscular dystrophy is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="mdef-cmd.Diagnosis">
        <title>Diagnosis</title>
        <sec id="mdef-cmd.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD) manifests in infancy as congenital muscular dystrophy (CMD) (referred to as early-onset <italic toggle="yes">LAMA2</italic> MD in this <italic toggle="yes">GeneReview</italic>) or as childhood onset limb-girdle type muscular dystrophy (referred to as late-onset <italic toggle="yes">LAMA2</italic> MD in this <italic toggle="yes">GeneReview</italic>).</p>
          <p>Individuals with early-onset <italic toggle="yes">LAMA2</italic> MD are often categorized by:</p>
          <list list-type="bullet">
            <list-item>
              <p>Immunohistochemical (IHC) staining on muscle or skin biopsy as having complete or partial deficiency of laminin &#x003b1;2, the protein encoded by <italic toggle="yes">LAMA2</italic>;</p>
            </list-item>
            <list-item>
              <p>The inability to ambulate (a manifestation of complete laminin &#x003b1;2 deficiency) or ability to ambulate (a manifestation of partial laminin &#x003b1;2 deficiency).</p>
            </list-item>
          </list>
        </sec>
        <sec id="mdef-cmd.Testing">
          <title>Testing</title>
          <p>Serum CK concentration is typically elevated for both complete and partial laminin &#x003b1;2 deficiency.</p>
          <list list-type="bullet">
            <list-item>
              <p>In the first years of life, serum CK concentration may be more than fourfold normal values [<xref ref-type="bibr" rid="mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>In one study, maximum serum CK concentrations ranged from 593 IU/L to 838 IU/L in partial laminin &#x003b1;2 deficiency and 840 IU/L to 6987 IU/L in complete laminin &#x003b1;2 deficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>]; normal range is between 200 and 400 depending on the laboratory.</p>
            </list-item>
            <list-item>
              <p>Children with complete laminin &#x003b1;2 deficiency who do not achieve walking usually have a serum CK concentration of more than 1000 IU in the first two years of life, with a subsequent decrease in levels.</p>
            </list-item>
          </list>
          <p><bold>Immunohistochemistry (IHC) of muscle or skin biopsy.</bold> Expression of laminin &#x003b1;2 is evaluated by commercially available antibodies whose epitopes have been mapped; the importance of using antibodies directed against different fragments of the laminin &#x003b1;2 chain has been demonstrated [<xref ref-type="bibr" rid="mdef-cmd.REF.he.2001.1319">He et al 2001</xref>]. Useful antibodies include those directed against (1) the 80-kd fragment of the carboxy-terminal LG region, (2) the 300-kd amino-terminus fragment, and (3) the entire laminin &#x003b1;2 chain (see <xref ref-type="sec" rid="mdef-cmd.Molecular_Genetics">Molecular Genetics</xref>, <bold>Normal gene product</bold>).</p>
          <p>In 51 individuals with confirmed laminin &#x003b1;2 deficiency, 33 had complete laminin &#x003b1;2 deficiency and 13 had partial deficiency on IHC [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
          <p>Note: (1) A consequence of complete deficiency of laminin &#x003b1;2 , encoded by <italic toggle="yes">LAMA2</italic>, is complete merosin deficiency because laminin &#x003b1;2 is one of three peptide chains that comprise merosin. Merosin (also known as laminin-211) is a heterotrimer comprising the laminin chains &#x003b1;2, &#x003b2;1, and &#x003b3;1, each encoded by a different gene (see <xref ref-type="sec" rid="mdef-cmd.Molecular_Genetics">Molecular Genetics</xref>). Because merosin deficiency can be primary in <italic toggle="yes">LAMA2</italic>-related muscular dystrophy or secondary in the dystroglycanopathies (also known as &#x003b1;-dystroglycan-related dystrophy), the term &#x0201c;merosin deficiency&#x0201d; is no longer used because it is not sufficiently specific (see <related-object link-type="booklink" source-id="gene" document-id="cmd-overview" document-type="chapter">Congenital Muscular Dystrophy Overview</related-object> and <xref ref-type="bibr" rid="mdef-cmd.REF.hara.2011.939">Hara et al [2011]</xref>). Of note, early reports of laminin &#x003b1;2 or merosin deficiency generated confusion because they did not distinguish between a direct result of inactivation of <italic toggle="yes">LAMA2</italic> and an indirect effect of a dystroglycanopathy. (2) In order to appreciate the reduced laminin &#x003b1;2 chain expression seen in partial laminin &#x003b1;2 deficiency, it may be necessary to use the antibody to the 300-kd fragment. (3) In order to differentiate partial deficiency of laminin &#x003b1;2 caused by mutation of <italic toggle="yes">LAMA2</italic> from an indirect result of a dystroglycanopathy, additional IHC staining with IgM antibodies against glycosylated epitopes of &#x003b1;-dystroglycan (IIH6 or VIA41) must be used [<xref ref-type="bibr" rid="mdef-cmd.REF.naom.1998.495">Naom et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.he.2001.1319">He et al 2001</xref>]. (4) In laminin &#x003b1;2 deficiency, staining for laminin &#x003b1;4 and &#x003b1;5 (which are upregulated) is increased [<xref ref-type="bibr" rid="mdef-cmd.REF.sewry.1997.169">Sewry et al 1997</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.he.2001.1319">He et al 2001</xref>].</p>
          <p>Hematoxylin and eosin staining of muscle. Characteristic findings are a dystrophic process early in infancy, including active degeneration, atrophic fibers, increased extracelluar matrix connective tissue, and areas of increased inflammation. Regenerating fibers, while present, are less than anticipated for the degree of degeneration [<xref ref-type="bibr" rid="mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</xref>].</p>
          <p>
            <bold>Brain MRI</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Abnormal white matter signal</bold> on T<sub>2</sub>-weighted brain MRI is observed in cerebral areas that are myelinated in the developing brain (i.e., subcortical and periventricular areas) with sparing of those areas that are myelinated later in life (i.e., corpus callosum and internal capsule) [<xref ref-type="bibr" rid="mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</xref>]. These abnormalities (likely secondary to leaky basal laminar connections and increased water content) do not represent areas of demyelination and are detected in some children as early as age six months [<xref ref-type="bibr" rid="mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</xref>] and consistently by age one year in those with the early onset form [<xref ref-type="bibr" rid="mdef-cmd.REF.leite.2005.190">Leite et al 2005</xref>]. The brain MRI findings are seen in both complete and partial laminin &#x003b1;2 deficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Structural brain abnormalities,</bold> observed in 5% of affected individuals, may include occipital pachygyria or agyria and pontocerebellar atrophy with accompanying variable cognitive impairment [<xref ref-type="bibr" rid="mdef-cmd.REF.mercuri.2001.297">Mercuri et al 2001</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.aslan.2005.308">Aslan et al 2005</xref>].</p>
            </list-item>
          </list>
          <sec id="mdef-cmd.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">LAMA2</italic> (encoding the laminin subunit &#x003b1;2 protein) is the only gene in which mutation is known to cause <italic toggle="yes">LAMA2</italic>-related muscular dystrophy.</p>
            <table-wrap id="mdef-cmd.T.summary_of_molecular_genetic" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">LAMA2</italic>-Related Muscular Dystrophy</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">LAMA2</italic>
                    </td>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">60%-80%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon deletions&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_mdef-cmd.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">20%-40%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="mdef-cmd.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="mdef-cmd" object-id="mdef-cmd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="mdef-cmd.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="mdef-cmd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="mdef-cmd.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="mdef-cmd.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="mdef-cmd.TF.1.5">
                  <label>5. </label>
                  <p>Commonly reported pathogenic variants (exact prevalence in <italic toggle="yes">LAMA2</italic>-related muscular dystrophy population unknown) are discussed in <xref ref-type="sec" rid="mdef-cmd.Molecular_Genetics">Molecular Genetics</xref> and <xref ref-type="table" rid="mdef-cmd.T.selected_lama2_pathogenic_var">Table 2</xref> and include c.2901C&#x0003e;A, c.1854_1861dup, c.2048-2049del, c.7750-1713_78899-2153del4987 (deletion of exon 56), and c.7881T&#x0003e;G.</p>
                </fn>
                <fn id="mdef-cmd.TF.1.6">
                  <label>6. </label>
                  <p><xref ref-type="bibr" rid="mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al [1998]</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.hayashi.2001.350">Hayashi et al [2001]</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.di_blasi.2005.1582">Di Blasi et al [2005]</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al [2008]</xref></p>
                </fn>
                <fn id="mdef-cmd.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="mdef-cmd.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Clinical examination</bold> demonstrating motor delay and weakness or profound hypotonia in an infant without findings that suggest the diagnosis of <related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">spinal muscular atrophy</related-object> (SMA) (i.e., tongue fasciculation and areflexia)</p>
            </list-item>
            <list-item>
              <p>
                <bold>Elevated serum CK concentration</bold>
              </p>
            </list-item>
            <list-item>
              <p><bold>Brain MRI</bold> demonstrating bilateral white matter high-intensity signal on T<sub>2</sub>-weighted and FLAIR MRI in periventricular areas and subcortical cerebral hemispheres as early as age six months and consistently at age one year</p>
            </list-item>
            <list-item>
              <p><bold>Muscle biopsy</bold> with consistent dystrophic appearance, including degeneration, fiber atrophy, and increased extracellular matrix connective tissue</p>
            </list-item>
            <list-item>
              <p><bold>Immunohistochemistry (IHC)</bold> showing:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Complete or partial laminin &#x003b1;2 deficiency (muscle and skin)</p>
                </list-item>
                <list-item>
                  <p>Increased expression of laminin &#x003b1;4 and &#x003b1;5</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold><italic toggle="yes">LAMA2</italic> molecular genetic testing</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>If two mutated <italic toggle="yes">LAMA2</italic> alleles are identified by sequence analysis, the diagnosis of <italic toggle="yes">LAMA2</italic>-related muscular dystrophy is confirmed.</p>
                </list-item>
                <list-item>
                  <p>If only one <italic toggle="yes">LAMA2</italic> pathogenic variant is identified by sequence analysis, deletion/duplication analysis should be performed to identify the second mutated allele.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: In those with typical clinical presentation, serum CK concentration, and brain MRI findings, muscle or skin biopsy is not necessary; <italic toggle="yes">LAMA2</italic> molecular genetic testing can be used to confirm the clinical diagnosis.</p>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
          <p>Linkage analysis and evaluation of laminin &#x003b1;2 by immunohistochemistry in chorionic villi may be available in certain specialized laboratories [<xref ref-type="bibr" rid="mdef-cmd.REF.vainzof.2005.588">Vainzof et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="mdef-cmd.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="mdef-cmd.Clinical_Description">
          <title>Clinical Description</title>
          <p>The clinical manifestations of <italic toggle="yes">LAMA2</italic>-related muscular dystrophy range from severe early-onset congenital muscular dystrophy (CMD) (early-onset <italic toggle="yes">LAMA2</italic> MD) to mild later childhood-onset limb-girdle type muscular dystrophy (late-onset <italic toggle="yes">LAMA2</italic> MD).</p>
          <p>Those with severe disease have neonatal profound hypotonia, poor spontaneous movements, weak cry, and respiratory failure [<xref ref-type="bibr" rid="mdef-cmd.REF.jones.2001.649">Jones et al 2001</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.gilhuis.2002.30">Gilhuis et al 2002</xref>]. Failure to thrive, gastroesophageal reflux, aspiration, and recurrent chest infections necessitating frequent hospitalizations may accompany the early hypotonic presentation. As disease progresses, facial muscle weakness, temporomandibular joint contractures, and macroglossia may further impair feeding and can affect speech.</p>
          <p>Late-onset <italic toggle="yes">LAMA2</italic> MD is characterized by later-onset proximal weakness and delayed motor milestones. Affected individuals may show muscle hypertrophy and develop a rigid spine syndrome with joint contractures, usually most prominent in the elbows. Progressive respiratory insufficiency and scoliosis can occur [<xref ref-type="bibr" rid="mdef-cmd.REF.he.2001.1319">He et al 2001</xref>] along with cardiac arrhythmia and cardiomyopathy [<xref ref-type="bibr" rid="mdef-cmd.REF.carboni.2011.826">Carboni et al 2011</xref>].</p>
          <p>Affected individuals are often categorized clinically by the ability or inability to achieve independent ambulation. Infants with complete laminin &#x003b1;2 deficiency on IHC staining (see <xref ref-type="sec" rid="mdef-cmd.Testing">Testing</xref>) typically have weakness at birth or in the first six months of life and do not achieve independent ambulation, whereas those with partial laminin &#x003b1;2 deficiency are more likely to have a later-onset, milder clinical course and achieve independent ambulation. (See <xref ref-type="sec" rid="mdef-cmd.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref> for more details.)</p>
          <sec id="mdef-cmd.EarlyOnset_LAMA2Related_Muscula">
            <title>Early-Onset <italic toggle="yes">LAMA2</italic>-Related Muscular Dystrophy (CMD Phenotype)</title>
            <p><bold>Respiratory involvement</bold> in <italic toggle="yes">LAMA2</italic> MD is caused by a progressively restrictive chest wall that first involves weakness of the intercostal and accessory muscles. Early in childhood the thorax becomes stiff and chest wall compliance decreases, further contributing to alveolar hypoventilation, atelectasis, and mucous plugs with bronchial obstruction. These changes manifest as low lung volumes. Poor secretion clearance resulting from weak cough leads to recurrent chest infection. Swallowing difficulties and gastroesophageal reflux may increase the risk of aspiration. Chest infections may cause atelectasis, which along with limited pulmonary reserve, increases risk of acute respiratory failure in the setting of infection.</p>
            <p>Spinal deformity may result early in thoracic and lumbar lordosis, which contribute to the progressive restrictive respiratory insufficiency. Thoracic lordosis, with or without concomitant scoliosis, may cause the bronchial wall to be compressed by the anterior vertebral bodies.</p>
            <p>In late adolescence, cervical lordosis may progress to severe neck hyperextension with a significant effect on the quality of life, as well as swallowing and feeding difficulties that increase the risk of aspiration.</p>
            <p>The need for ventilatory support is most likely to occur during two time periods [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Between birth and age five years in the most severely affected children mainly due to respiratory muscle weakness, hypotonia, and fatigue. Depending on age, total hours of ventilatory support required, frequency of hospitalizations, and institutional practice patterns, ventilatory support may be noninvasive or mechanical with tracheostomy. Respiratory issues in these infants and young children often stabilize in the first years, likely as a result of improved muscle tone.</p>
              </list-item>
              <list-item>
                <p>Between ages ten and 15 years due to progressive restrictive lung disease leading to respiratory insufficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.wallgrenpettersson.2004.56">Wallgren-Pettersson et al 2004</xref>]. Most children in this age group with the early onset form do not have typical signs/symptoms of hypercapnia (i.e., headaches, attention difficulties, and drowsiness) but rather the more subtle findings including recurrent respiratory infections, failure to thrive, poor cough, and fatigue with feeding.</p>
              </list-item>
            </list>
            <p><bold>Feeding difficulties,</bold> consistent low weight, failure to thrive, and precipitous drop in weight with infections and hospitalizations are common. <xref ref-type="bibr" rid="mdef-cmd.REF.philpot.1999a.542">Philpot et al [1999a]</xref> reported weight below the third centile and feeding difficulties including: swallowing abnormalities, difficulty chewing, and prolonged feeding time. In a study of 46 individuals with <italic toggle="yes">LAMA2</italic> MD, 17 required enteral feeding, usually within the first year [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>]. Of note, children with early-onset <italic toggle="yes">LAMA2</italic> MD do not attain normal weight (see Management, <xref ref-type="sec" rid="mdef-cmd.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
            <p><bold>Joint contractures</bold> that are present in the first year of life progress slowly even in children receiving intensive daily physical therapy. Contractures tend to occur early in the shoulders, elbows, hips, and knees and later in the temporomandibular joints, distal joints, and cervical spine. Contractures often result in significant morbidity and interfere with activities of daily living.</p>
            <p>Hyperlaxity of the distal phalanges of the fingers is observed in a number of affected children.</p>
            <p><bold>Motor developmental milestones</bold> are delayed and often arrested. Most affected children do not acquire independent walking.</p>
            <p><xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al [2010]</xref> reported only 15% of individuals acquired independent ambulation, the majority of whom (72%) had partial laminin &#x003b1;2 deficiency on muscle biopsy. A smaller proportion gained the ability to walk with assistance but subsequently lost the ability.</p>
            <p>Individuals with complete laminin &#x003b1;2 deficiency were much less likely to achieve independent ambulation than those with partial deficiency.</p>
            <p><bold>Scoliosis,</bold> often aggravated by thoracic lordosis, is frequently observed from the first decade of life [<xref ref-type="bibr" rid="mdef-cmd.REF.bentley.2001.22">Bentley et al 2001</xref>]. It is slowly progressive and may contribute to respiratory insufficiency by restriction of the thorax and compression of the airway.</p>
            <p><bold>Facial muscle weakness</bold> and <bold>macroglossia</bold> may become significant in toddlers and children, resulting in typical elongated myopathic facies, with an open mouth and tongue protrusion.</p>
            <p><bold>Limitation of eye movements (ophthalmoparesis)</bold> may be evident as early as age two years. Initially, limitation of eye movement is most evident on upward (vertical) gaze; however, over time, lateral gaze may become impaired. Down gaze seems to be preserved, as are pupil size and pupillary reflex; ptosis is not observed [<xref ref-type="bibr" rid="mdef-cmd.REF.philpot.1999b.81">Philpot et al 1999b</xref>].</p>
            <p><bold>Central nervous system (CNS).</bold> Cognitive abilities are normal in the majority of affected individuals and do not correlate with brain MRI abnormalities [<xref ref-type="bibr" rid="mdef-cmd.REF.messina.2010.898">Messina et al 2010</xref>]; however, in a small proportion of individuals, intellectual disability and epilepsy were associated with bilateral occipital pachygyria [<xref ref-type="bibr" rid="mdef-cmd.REF.jones.2001.649">Jones et al 2001</xref>] or dysplastic cortical changes affecting predominantly the occipital and temporal regions [<xref ref-type="bibr" rid="mdef-cmd.REF.sunada.1995.2084">Sunada et al 1995</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.pini.1996.316">Pini et al 1996</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.philpot.1999b.81">Philpot et al 1999b</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.leite.2005.190">Leite et al 2005</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
            <p>Cognitive impairment, reported in fewer than 7% of individuals [<xref ref-type="bibr" rid="mdef-cmd.REF.jones.2001.649">Jones et al 2001</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>], ranged from mild intellectual disability to communication difficulties.</p>
            <p>Absence seizures and partial seizures with secondary generalization develop in 8%-20% of affected children usually in late childhood; because lack of seizures is likely under-reported, the higher figure may be more accurate [<xref ref-type="bibr" rid="mdef-cmd.REF.jones.2001.649">Jones et al 2001</xref>]. Individuals with cortical dysplasia may develop refractory seizures [<xref ref-type="bibr" rid="mdef-cmd.REF.vigliano.2009.72">Vigliano et al 2009</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
            <p><bold>A progressive sensorimotor neuropathy</bold> with signs of dysmyelinization may be detected in childhood [<xref ref-type="bibr" rid="mdef-cmd.REF.di_muzio.2003.500">Di Muzio et al 2003</xref>]. These abnormalities are usually mild or clinically not significant. In contrast, needle EMG shows myopathic signs in the majority of individuals, even when performed early in infancy [<xref ref-type="bibr" rid="mdef-cmd.REF.quijanoroy.2004.292">Quijano-Roy et al 2004</xref>].</p>
            <p>Cardiac involvement does not seem to be a major complication of <italic toggle="yes">LAMA2</italic> MD. Although early ultrasound studies in merosin deficiency (in which molecular genetic studies were incomplete) found decreased ejection fraction and subclinical left ventricular hypokinesis in approximately one third of affected individuals [<xref ref-type="bibr" rid="mdef-cmd.REF.spyrou.1998.474">Spyrou et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.jones.2001.649">Jones et al 2001</xref>], these results have not been confirmed and cardiac failure is rarely reported [<xref ref-type="bibr" rid="mdef-cmd.REF.gilhuis.2002.30">Gilhuis et al 2002</xref>].</p>
            <p>Anecdotal reports have included one report of cardiac arrhythmia requiring ablation or medical treatment and two reports of sudden death with cardiac arrhythmia, one in the context of a viral infection [SJ Quijano-Roy 2010, personal communication] and recently in an adult with partial merosin deficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.carboni.2011.826">Carboni et al 2011</xref>].</p>
            <p>With improved respiratory management resulting in longer survival, cardiac manifestations may be recognized more commonly in older individuals.</p>
            <p>Secondary pulmonary hypertension may be observed as a complication of respiratory insufficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
          </sec>
          <sec id="mdef-cmd.LateOnset_LAMA2Related_Muscular">
            <title>Late-Onset <italic toggle="yes">LAMA2</italic>-Related Muscular Dystrophy (LGMD Phenotype)</title>
            <p>Rarely individuals with partial laminin &#x003b1;2 deficiency have onset after infancy manifest as delay in walking or proximal muscle weakness, and are typically classified as having <related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">limb-girdle muscular dystrophy</related-object>. Individuals with this milder phenotype may show muscle pseudohypertrophy and/or rigid spine. In general, additional findings include high serum creatine kinase (CK) concentrations, dystrophic muscle changes, abnormal brain MRI, and abnormal nerve conduction studies.</p>
            <p>A recent case report describes two sibs with classic brain MRI white matter abnormalities, seizures, and proximal muscle weakness. In addition, muscle histology show dystrophic features, rimmed vacuoles, and partial decrease in laminin &#x003b1;2 staining; molecular testing confirmed the diagnosis [<xref ref-type="bibr" rid="mdef-cmd.REF.rajakulendran.2011.590">Rajakulendran et al 2011</xref>].</p>
          </sec>
          <sec id="mdef-cmd.Other_Studies_in_Persons_with_L">
            <title>Other Studies in Persons with <italic toggle="yes">LAMA2</italic> MD</title>
            <p>Visual evoked potentials and somatosensory potentials show increased latency in older children with normal visual function, even in those with white matter involvement of the occipital lobes and abnormal visual evoked potentials [<xref ref-type="bibr" rid="mdef-cmd.REF.mercuri.1998.399">Mercuri et al 1998</xref>].</p>
            <p>Pathophysiology. <italic toggle="yes">LAMA2</italic> MD is not a true leukodystrophy; the physiologic basis of the white matter abnormalities observed on brain MRI is not fully understood. Although white matter changes were initially thought to represent hypomyelination, recent studies using both brain MR spectroscopy and diffusion weighted imaging have identified abnormal water content thought to be related to leaky basement membrane connections rather than hypomyelination [<xref ref-type="bibr" rid="mdef-cmd.REF.leite.2005.190">Leite et al 2005</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</xref>].</p>
            <p>In particular, brain MR spectroscopy (MRS) reveals very low N-acetylaspartate, N-acetylaspartylglutamate, creatine, and phosphocreatine, findings that suggest a relative astrocytosis and an increased water signal with possible edema within the white matter [<xref ref-type="bibr" rid="mdef-cmd.REF.leite.2005.190">Leite et al 2005</xref>]. These findings are hypothesized to result from increased permeability of the blood-brain barrier due to the absence of laminin &#x003b1;2 in the basal lamina of the cells of the cerebral blood vessels.</p>
            <p>Laminin &#x003b1;2 is also present in Schwann cells. Thus, deficiency of laminin &#x003b1;2 may partially explain the progressive sensorimotor axonal polyneuropathy seen in many individuals with laminin &#x003b1;2 deficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.quijanoroy.2004.292">Quijano-Roy et al 2004</xref>]; however, the clinical significance of the neuropathy and its contribution to the primary muscle disorder are not currently understood.</p>
            <p>In post-mortem studies, the white matter of the brain is pale and spongiform with astrocytosis and demyelinization.</p>
          </sec>
        </sec>
        <sec id="mdef-cmd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Prognostication of clinical severity depends on several variables including: age at first symptom onset, presence/absence of the protein laminin &#x003b1;2 on IHC analysis, pathogenic variant type, and, if known, effect of the variant on protein function.</p>
          <p>Genotype-phenotype correlations in <italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD) are emerging through publications of small cohorts. A recently launched effort, CMD GaP (genotype and phenotype), led by the National Center for Biotechnology Information (NCBI) and the National Institute of Neurologic Disease and Stroke (NINDS) (both of the National Institutes of Health), Cure CMD, and a consortium of national and international laboratories (<related-object source-id="gene" document-id="mdef-cmd" object-id="mdef-cmd.molgen.TA">Table A</related-object>) will contribute.</p>
          <p>In a study of 51 individuals with confirmed <italic toggle="yes">LAMA2</italic> MD, those with complete deficiency presented earlier (age &#x0003c;7 days) (p=0.0073), were more likely to lack independent ambulation (p=0.0215), and were more likely to require enteral feeding (p=0.0099) and ventilatory support (p=0.0354) than those with partial laminin &#x003b1;2 deficiency [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
          <p>Complete absence of laminin &#x003b1;2 and the early-onset severe phenotype in general are caused by pathogenic nonsense variants [<xref ref-type="bibr" rid="mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>]; however, exceptions occur, including an individual homozygous for a pathogenic nonsense variant who achieved ambulation [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
          <p>Partial deficiency can be caused by homozygosity for missense variants and for in-frame deletions and by compound heterozygosity for a null variant and an in-frame deletion or exon-skipping variant [<xref ref-type="bibr" rid="mdef-cmd.REF.naom.1998.495">Naom et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.tezak.2003.103">Tezak et al 2003</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.siala.2007.199">Siala et al 2007</xref>]. However, in-frame deletions involving the G-domain that mediates binding to &#x003b1;-dystroglycan and &#x003b1;7&#x003b2;1 integrin result in a severe early-onset phenotype even when IHC analysis reveals partial laminin &#x003b1;2 deficiency on muscle biopsy [<xref ref-type="bibr" rid="mdef-cmd.REF.naom.1998.495">Naom et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.tezak.2003.103">Tezak et al 2003</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.siala.2007.199">Siala et al 2007</xref>].</p>
          <p>Partial laminin &#x003b1;2 deficiency may also be caused by a pathogenic variant in the conserved cysteine residues on the short arm of the laminin &#x003b1;2 protein [<xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>].</p>
          <p>Although the ability to ambulate is generally correlated with the presence of laminin &#x003b1;2 on muscle biopsy, a limited number of children with complete laminin &#x003b1;2 deficiency have achieved ambulation and conversely some children with partial laminin &#x003b1;2 deficiency have had early-onset disease and no ambulation. <xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al [2010]</xref> found that among 51 persons studied, two of 33 with absence of laminin &#x003b1;2 staining on muscle biopsy achieved independent ambulation, one with a heterozygous frameshift variant and a pathogenic missense variant, and one homozygous for a Kenyan founder variant (<xref ref-type="table" rid="mdef-cmd.T.selected_lama2_pathogenic_var">c.7881T&#x0003e;G</xref>). Of note, three in this cohort with the Kenyan founder variant did not acquire ambulation, demonstrating the lack of consistent genotype-phenotype correlations and variability in clinical presentation.</p>
          <p>See <xref ref-type="sec" rid="mdef-cmd.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic variants</bold> for the phenotypes associated with several commonly reported pathogenic variants.</p>
        </sec>
        <sec id="mdef-cmd.Nomenclature">
          <title>Nomenclature</title>
          <p><italic toggle="yes">LAMA2</italic>-related muscular dystrophy is also known as &#x0201c;merosin-deficient congenital muscular dystrophy type 1A (MDC1A [muscular dystrophy, congenital, type 1A])&#x0201d; in the international classification, based on the observation (prior to discovery of <italic toggle="yes">LAMA2</italic>) that individuals with CMD often showed complete or partial absence of merosin by IHC analysis of muscle biopsy.</p>
          <p>A nomenclature system that describes which chains are present in each laminin isoform gives merosin the name laminin-211 because it comprises chains &#x003b1;2, &#x003b2;1, and &#x003b3;1.</p>
          <p>Previously the terms "complete and partial merosin deficiency" based on IHC staining were used before it was known that the defect was laminin &#x003b1;2 deficiency. These old diagnostic terms are not relevant now, given that: (1) the diagnosis of <italic toggle="yes">LAMA2</italic>-related muscular dystrophy can be made with certainty by detection of biallelic pathogenic variants in <italic toggle="yes">LAMA2</italic>; and (2) merosin deficiency can be primary, caused by biallelic pathogenic variants in <italic toggle="yes">LAMA2</italic>, or secondary (indirect), caused by biallelic pathogenic variants in one of the dystrophinopathy genes (See <xref ref-type="sec" rid="mdef-cmd.Testing">Testing</xref>, <bold>Immunohistochemistry</bold>).</p>
        </sec>
        <sec id="mdef-cmd.Prevalence">
          <title>Prevalence</title>
          <p>Exact prevalence of early-onset <italic toggle="yes">LAMA2</italic> MD is unknown. In general, the prevalence of CMDs has been estimated between 0.7/100,000 (based on a 1996 report from northeast Italy that predates molecular genetic testing [<xref ref-type="bibr" rid="mdef-cmd.REF.mostacciuolo.1996.277">Mostacciuolo et al 1996</xref>]) and 2.5/100,000 (in a study in western Sweden [<xref ref-type="bibr" rid="mdef-cmd.REF.darin.2000.1">Darin &#x00026; Tulinius 2000</xref>]).</p>
          <p>Regional prevalence is variable: early-onset <italic toggle="yes">LAMA2</italic> MD accounts for about 30% of the CMD cases in European countries, but only 6% in Japan [<xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>].</p>
        </sec>
      </sec>
      <sec id="mdef-cmd.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">LAMA2</italic>.</p>
      </sec>
      <sec id="mdef-cmd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Early-onset <italic toggle="yes">LAMA2</italic>-related muscular dystrophy is in the differential diagnosis of infantile hypotonia with or without respiratory distress and delayed acquisition of motor milestones. Late-onset <italic toggle="yes">LAMA2</italic> MD is in the differential diagnosis of childhood-onset weakness of the limb-girdle type.</p>
        <p><bold>Early-onset <italic toggle="yes">LAMA2</italic> MD</bold> needs to be differentiated from:</p>
        <list list-type="bullet">
          <list-item>
            <p>Other forms of congenital muscular dystrophy (CMD) (see <related-object link-type="booklink" source-id="gene" document-id="cmd-overview" document-type="chapter">CMD Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p>Congenital myopathies</p>
          </list-item>
          <list-item>
            <p>Congenital metabolic myopathies</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter">Congenital myotonic dystrophy</related-object>
            </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cms" document-type="chapter">Congenital myasthenic syndromes</related-object> (CMS)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">Spinal muscular atrophy</related-object> (SMA)</p>
          </list-item>
        </list>
        <p>Early-onset <italic toggle="yes">LAMA2</italic> MD is easily distinguished from the above disorders because they are not typically associated with: (1) high serum CK concentrations, (2) merosin deficiency detected by immunohistochemical (IHC) staining of muscle or skin biopsy, or (3) white matter changes on brain MRI.</p>
        <p>Clinical examination can also assist in distinguishing them from <italic toggle="yes">LAMA2</italic> MD. Although all may present with profound hypotonia (with frog leg posture of the legs), chest deformity, and breathing and feeding problems, the following findings may be distinguishing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital myopathies may show some fibrosis on muscle biopsy, but are excluded mainly based on the presence of diagnostic structural abnormalities on light and electron microscopy (e.g., <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="cco" document-type="chapter">central core myopathy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="mtm" document-type="chapter">centronuclear/myotubular myopathy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter">minicore myopathy</related-object>). These congenital myopathies (as well as the metabolic and myasthenic myopathies) may show progressive improvement of tone and strength; diffuse joint contractures do not occur even in those with severe disease.</p>
          </list-item>
          <list-item>
            <p>Distinctive clinical findings may be observed from an early age in some: ophthalmoplegia and facial bulbar weakness in <related-object link-type="booklink" source-id="gene" document-id="mtm" document-type="chapter">centronuclear/myotubular myopathy</related-object>; facial and bulbar weakness in <related-object link-type="booklink" source-id="gene" document-id="nem" document-type="chapter">nemaline myopathy</related-object> and <related-object link-type="booklink" source-id="gene" document-id="cms" document-type="chapter">congenital myasthenic syndromes</related-object> (CMS); malignant hyperthermia in central core disease; striking motor variability in CMS and metabolic myopathies.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter">Spinal muscular atrophy</related-object> (SMA) shows relatively rapid motor impairment and tongue fasciculations. EMG and muscle biopsy findings suggest a denervation-reinnervation profile; nerve conduction studies are normal.</p>
          </list-item>
        </list>
        <p>Secondary deficiency of the protein laminin &#x003b1;2 may result from another type of dystroglycanopathy (see <related-object link-type="booklink" source-id="gene" document-id="cmd-overview" document-type="chapter">CMD Overview</related-object>).</p>
        <p><bold>Late-onset <italic toggle="yes">LAMA2</italic> MD</bold> (the limb-girdle muscular dystrophy phenotype) needs to be differentiated from other forms of limb girdle muscular dystrophy (see <related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">LGMD Overview</related-object>). Elbow contractures, high serum CK concentrations, and prominent spinal rigidity may lead to a phenotype overlapping with <related-object link-type="booklink" source-id="gene" document-id="edmd" document-type="chapter">Emery-Dreifuss myopathy</related-object> (EDMD); however, in contrast to EDMD, <italic toggle="yes">LAMA2</italic> MD lacks major cardiac involvement.</p>
      </sec>
      <sec id="mdef-cmd.Management">
        <title>Management</title>
        <sec id="mdef-cmd.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of a child diagnosed with <italic toggle="yes">LAMA2</italic>-related muscular dystrophy following the initial diagnosis, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of feeding, nutrition, and bone health: measurement of weight and serum concentrations of vitamin D and calcium</p>
            </list-item>
            <list-item>
              <p>Systematic inquiry of parents/caregivers regarding digestive complications, in particular dysphagia, GE-reflux, and constipation. Frequent choking, prolonged feeding, and nocturnal cough may identify swallowing and gastroesophageal disorders. Additional assessment may include endoscopy, manometry, PH-meter studies, and videofluoroscopy.</p>
            </list-item>
            <list-item>
              <p>Lung function tests that ideally include spirometry (forced vital capacity, forced expired volume in the first second [FEV-1]) and assessment of cough effectiveness (cough peak flow and maximum inspiratory and expiratory pressures)</p>
              <list list-type="bullet">
                <list-item>
                  <p>Evaluate older children with an FVC lower than 60% of the predicted value with polysomnography or, if polysomnography is not routinely performed, overnight oximetry.</p>
                </list-item>
                <list-item>
                  <p>In those using orthopedic trunk braces or orthoses, assess pulmonary function with and without the brace to determine whether thoracic excursion (and thus ventilator function) is impaired.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Evaluation for nocturnal hypoventilation in children with a history of recurrent respiratory infections, failure to thrive, poor cry, and/or feeding fatigue</p>
            </list-item>
            <list-item>
              <p>Physical therapy assessment of muscle strength and joint mobility</p>
            </list-item>
            <list-item>
              <p>Assessment of the spine by an orthopedist regarding the need for early bracing</p>
            </list-item>
            <list-item>
              <p>Evaluation by a child neurologist for seizures or unexplained fainting or loss of consciousness.</p>
            </list-item>
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>Neuropsychological testing if learning or behavioral deficiencies are identified</p>
            </list-item>
            <list-item>
              <p>Evaluation by a cardiologist including electrocardiogram and echocardiogram</p>
            </list-item>
            <list-item>
              <p>Evaluation of respite care services for caregivers</p>
            </list-item>
            <list-item>
              <p>Educational planning to place the child with necessary support in the least restrictive educational environment</p>
            </list-item>
          </list>
        </sec>
        <sec id="mdef-cmd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="mdef-cmd.EarlyOnset_LAMA2_MD">
            <title>Early-Onset <italic toggle="yes">LAMA2</italic> MD</title>
            <p><bold>Nutrition/weight.</bold> In the absence of evidence-based target BMI or weight charts, the recommendation is to weigh the child serially and assess the frequency of chest infections and hospitalizations. Weight needs to increase annually by small increments. Since these children are usually non-ambulatory and muscular mass is reduced, normalization of weight to standard weights is not the goal. In contrast, excess weight may contribute to reduced motor function, resulting in increased respiratory dysfunction.</p>
            <p>If weight plateaus or decreases, assessment of nutrition and diet, speech and swallowing, and respiratory function by a multidisciplinary team of specialists is recommended:</p>
            <list list-type="bullet">
              <list-item>
                <p>The patient or caregiver may need to be prompted to recall dietary concerns including lengthy meal times, limited food intake, and/or significant constipation [<xref ref-type="bibr" rid="mdef-cmd.REF.philpot.1999a.542">Philpot et al 1999a</xref>]. Non-ambulant school-age children (because they require assistance to use the restroom) may consciously restrict liquid intake. Limited hydration, choice of diet, and lack of movement may all contribute to constipation, leading to further restriction of oral intake.</p>
              </list-item>
              <list-item>
                <p>The nutritionist can review dietary fiber, total liquid consumption, and the need for laxatives (e.g., Miralax<sup>&#x000ae;</sup>, macromolecules FORLAX<sup>&#x000ae;</sup>) to optimize caloric intake during periods of growth.</p>
              </list-item>
              <list-item>
                <p>If weight continues to decline, respiratory assessment to evaluate for pulmonary infection is indicated.</p>
              </list-item>
            </list>
            <p>Adequate weight gain may be achieved by increasing the caloric content of formulas in infants and by supplementary hypercaloric protein drinks in older children.</p>
            <list list-type="bullet">
              <list-item>
                <p>Infants with persistently poor weight gain and frequent pulmonary infections should be referred to a gastroenterologist:</p>
              </list-item>
              <list-item>
                <p>Gastroesophageal reflux is treated as needed.</p>
              </list-item>
              <list-item>
                <p>A nasogastric tube or percutaneous gastrostomy may help avoid aspiration pneumonia and improve nutritional status.</p>
              </list-item>
              <list-item>
                <p>Failure to thrive may require supplemental feeding and gastrostomy with or without Nissen fundoplication [<xref ref-type="bibr" rid="mdef-cmd.REF.philpot.1999a.542">Philpot et al 1999a</xref>].</p>
              </list-item>
              <list-item>
                <p>Children with poor intake or vomiting may require enteral feeding or intravenous fluid therapy to avoid hypoglycemia and metabolic decompensation.</p>
              </list-item>
            </list>
            <p>Calcium and vitamin D supplementation is recommended to support bone growth and strength and to prevent future osteopenia.</p>
            <p><bold>Respiratory function testing.</bold> Training five year olds to perform spirometry during regular clinic visits may allow them to become adept at performing pulmonary function tests by age six years. (Note: A training effect may lead to an initial improvement in spirometric values.) For those who cannot use a standard mouth piece due to facial weakness, a buco-nasal mask adapter or scuba mouth piece can be used.</p>
            <p>Pulmonary function tests ideally include spirometry (forced vital capacity [FVC], forced expired volume in the first second [FEV-1]) and measures of cough effectiveness (cough peak flow and maximum inspiratory and expiratory pressures). Note: In those using orthopedic trunk braces or orthoses, assess pulmonary function with and without the brace to determine if thoracic excursion is impaired.</p>
            <p>An FVC less than 60% of the predicted value has been associated with sleep-disordered breathing; an FVC less than 40% of predicted has been associated with high risk for nocturnal hypoventilation [<xref ref-type="bibr" rid="mdef-cmd.REF.mellies.2003.123">Mellies et al 2003</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Those with an FVC less than 60% of predicted or clinical evidence of disordered sleep (daytime somnolence, morning headaches, hypercarbia) should undergo an overnight sleep study (polysomnogram) to evaluate for night-time hypoventilation, hypercapnia, and obstructive sleep apnea.</p>
              </list-item>
              <list-item>
                <p>Those with an FVC less than 60% of predicted and hypercapnia, hypoxemia, and/or significant aspiration of food or refluxed gastric contents should be referred to a pulmonologist.</p>
              </list-item>
              <list-item>
                <p>Assessment of hypoventilation, night-time and daytime hypercapnea is indicated in children with signs of sleep-related difficulties (e.g., morning headaches, attention difficulties, hypersomnolence, increased fatigue), weight loss, recurrent pulmonary infections, a weak cry, and/or FVC less than 60% of predicted.</p>
              </list-item>
              <list-item>
                <p>Because early respiratory insufficiency may not be detected by diurnal tests, polysomnography (including end-tidal CO2 measurements) can be used to evaluate for nocturnal hypoventilation and other sleep-related breathing difficulties, such as apnea (both obstructive and central) and hypopnea, which are usually more pronounced during REM sleep. (The predominance of findings in REM sleep may be the result of diminished respiratory drive, atonia of the upper airway and intercostal muscles, and weakness of the diaphragm.)</p>
              </list-item>
            </list>
            <p><bold>Assistance with coughing.</bold> Weak/ineffective cough can lead to progressive atelectasis, infection, and respiratory failure in those with diminished lung capacity.</p>
            <p>Daily intermittent positive pressure breathing (IPPB) may improve diminished compliance, peak cough flow, and ability to clear secretions. It has been shown to promote expansion of the thorax, prevent or treat atelectasis, and decrease the risk of lower-respiratory infections [<xref ref-type="bibr" rid="mdef-cmd.REF.mellies.2005.543">Mellies et al 2005</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.wang.2010">Wang et al 2010</xref>]. Positive pressure breathing can be administered by IPPB or a mechanical in-exsufflator (Cough Assist), or attained through breath-stacking maneuvers using a bag valve mask. Patients with weak cough (low cough peak flow, maximum and inspiratory pressures &#x0003c;60 cm H2O, and FVCs &#x0003c;60% predicted) can benefit from use of positive pressure breathing once or twice a day and then as needed during respiratory infections. Night-time ventilator support once initiated also helps inflate the lungs, allowing for better tidal volume and ventilation, and thus preventing atelectasis.</p>
            <p>Because of abdominal muscle weakness and the need for high positive pressures, an abdominal belt can lead to better results, efficacy, and tolerance [<xref ref-type="bibr" rid="mdef-cmd.REF.gu_rin.2010.866">Gu&#x000e9;rin et al 2010</xref>].</p>
            <p><bold>Noninvasive ventilation support</bold> is indicated in the setting of:</p>
            <list list-type="bullet">
              <list-item>
                <p>Daytime hypercapnea and/or nocturnal hypoventilation</p>
              </list-item>
              <list-item>
                <p>Evidence on polysomnogram of sleep-disordered breathing (even without hypoventilation)</p>
              </list-item>
              <list-item>
                <p>Recurrent chest infections or atelectasis (in the absence of either daytime hypercapnea or nocturnal hypoventilation) in infants and toddlers [SJ Quijano-Roy, personal communication]</p>
              </list-item>
            </list>
            <p>Noninvasive ventilator interfaces include nasal pillows, nasal masks, and full face masks, all of which come with head gear. Of note, it is difficult to fit masks to infants; toddlers often fight the masks.</p>
            <p>In children, alternating mask interfaces is recommended to prevent the progressive under-bite and midface hypoplasia that result from the bone remodeling associated with long-term use of nasal masks from an early age. Although the nasal mask causes more bite and mid-face problems than does the full face mask, the full face mask should be used with caution because of the risk of suffocation in a child who vomits into the mask and is unable to remove it.</p>
            <p>In patients with severe lordosis/scoliosis and chronic cough or recurrent infections, chest CT may be needed to evaluate for chronic atelectasis and airway compression by the vertebral bodies</p>
            <p>During adolescence ventilatory support is often only needed during sleep with noninvasive pressure support. Assessment of daytime hypercapnea is needed beginning in late adolescence or if patient experiences increasing fatigue, chest infections, or failure to thrive. If daytime ventilation is required, ventilation via tracheostomy may be indicated.</p>
            <p><bold>Joint contractures.</bold> Physical therapy including daily stander placement, stretching activities, and pool (swimming) therapy can assist in maintenance of some range of motion.</p>
            <p>Splints, orthoses, and night positioning by casts are used to prevent progression of joint deformities.</p>
            <p>Non-ambulant children require standing frames for postural support.</p>
            <p>Durable medical equipment support including power wheelchair fitting is essential for non-ambulant toddlers.</p>
            <p><bold>Scoliosis</bold> may need orthopedic and surgical treatment [<xref ref-type="bibr" rid="mdef-cmd.REF.bentley.2001.22">Bentley et al 2001</xref>]. When needed, specific trunk orthotics or braces that do not restrict the thorax either through compression or limitation of thoracic movements are recommended [<xref ref-type="bibr" rid="mdef-cmd.REF.wang.2010">Wang et al 2010</xref>]. Their use may improve upright posture and delay spinal fusion until early puberty, providing that bracing does not interfere with respiration by causing chest compression [<xref ref-type="bibr" rid="mdef-cmd.REF.wang.2010">Wang et al 2010</xref>].</p>
            <p>If cervical lordosis progresses in late adolescence, posterior head support (using trunk braces or wheelchair supports) can prevent neck hyperextension.</p>
            <p><bold>Cardiomyopathy.</bold> Right heart failure due to respiratory insufficiency requires adequate mechanical ventilation. Primary left heart failure or rhythm disturbances require typical age-appropriate treatment.</p>
            <p>Seizures are generally well controlled with routine administration of antiepileptic drugs. Refractory seizures in those with cortical dysplasia may require polytherapy.</p>
            <p><bold>Developmental delay/cognitive impairment.</bold> Early intervention with physical, occupational, and speech therapy along with a multidisciplinary medical team provide the best possible outcome.</p>
            <p><bold>Other.</bold> Surgery to correct facial function and address cosmetic concerns has been performed [<xref ref-type="bibr" rid="mdef-cmd.REF.jones.2012.e141">Jones &#x00026; Waite 2012</xref>].</p>
          </sec>
          <sec id="mdef-cmd.LateOnset_LAMA2_MD">
            <title>Late-Onset <italic toggle="yes">LAMA2</italic> MD</title>
            <p>These patients need mainly respiratory and orthopedic care due to the risk of progressive respiratory insufficiency and joint and spinal deformities. Regular physical therapy for stretching limbs, shoulder and pelvic girdle, and spine is mandatory.</p>
            <p>Antiepileptic drugs should be used to treat seizures.</p>
          </sec>
        </sec>
        <sec id="mdef-cmd.Surveillance">
          <title>Surveillance</title>
          <p>Standards of care have been reviewed recently [<xref ref-type="bibr" rid="mdef-cmd.REF.wang.2010">Wang et al 2010</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jcn.sagepub.com/content/25/12/1559.long">full text</ext-link>).</p>
          <p>
            <bold>Early-onset <italic toggle="yes">LAMA2</italic> MD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At least biannual evaluations during the first five years by a nutritionist and gastroenterologist to monitor weight gain and to identify early recurrent aspiration</p>
            </list-item>
            <list-item>
              <p>At least annual follow up with a pulmonologist to assess respiratory function. After age four to six years: annual pulmonary function testing including assessment of forced vital capacity (FVC).</p>
            </list-item>
            <list-item>
              <p>Annual measurement of FVC to allow trending of FVC</p>
            </list-item>
            <list-item>
              <p>Annual evaluation of strength and joint range of motion by a physical therapist</p>
            </list-item>
            <list-item>
              <p>At least annual evaluation of the spine by an orthopedist. Note: (1) More frequent evaluations are warranted during periods of rapid growth, loss of function, and/or progression of deformities. (2) Annual lateral spinal x-rays (in addition to the standard anterior-posterior x-rays) can be used to evaluate the anterior posterior intra-thoracic cavity diameter; however, if respiratory function declines rapidly without known cause or without prior spinal surgery, a CT may be needed.</p>
            </list-item>
            <list-item>
              <p>Cardiac monitoring:</p>
              <list list-type="bullet">
                <list-item>
                  <p>In the absence of symptoms, evaluation by a cardiologist including electrocardiogram and echocardiogram at age five years, ten years, and then every two years</p>
                </list-item>
                <list-item>
                  <p>In patients with severe respiratory insufficiency on mechanical ventilation, annual echocardiography (required)</p>
                </list-item>
                <list-item>
                  <p>In patients reporting palpitations, increased fatigue, or loss of consciousness without a clear neurologic origin, cardiac evaluation including Holter monitor and echocardiogram (recommended)</p>
                </list-item>
                <list-item>
                  <p>Pre-surgical cardiac evaluation including Holter monitor, echocardiogram, and a dopamine test of cardiac function</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: The brain MRI findings seen in both complete and partial laminin &#x003b1;2 deficiency do not need to be followed with serial scans over time [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>].</p>
          <p>
            <bold>Late-onset <italic toggle="yes">LAMA2</italic> MD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Respiratory. Monitor for respiratory insufficiency with serial pulmonary function tests.</p>
            </list-item>
            <list-item>
              <p>Orthopedic. Monitor with frequent spinal examinations to detect scoliosis and assess bone health.</p>
            </list-item>
            <list-item>
              <p>Neurologic. Monitor to detect and treat seizures.</p>
            </list-item>
          </list>
        </sec>
        <sec id="mdef-cmd.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Succinylcholine in induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities</p>
            </list-item>
            <list-item>
              <p>Statin, cholesterol lowering medication, because of the risk of muscle damage</p>
            </list-item>
          </list>
        </sec>
        <sec id="mdef-cmd.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="mdef-cmd.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="mdef-cmd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><italic toggle="yes">LAMA2</italic>-related muscular dystrophy leads to a primary deficiency of the protein laminin &#x003b1;2 in the extracellular matrix of muscle, precipitating several downstream effects including: increased inflammation, increased fibrosis, increased apoptosis, and decreased regeneration.</p>
          <p>Several therapies have recently been tested in murine models that replicate disease pathogenesis (including the dyw and dy3k [neo cassettes in <italic toggle="yes">LAMA2</italic>] and dy2j [a spontaneously occurring pathogenic variant]). Current efforts to define standard operating protocols led by TREAT-NMD, a panel of international scientists and Cure CMD, have been posted at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.curecmd.org/resources-for-scientists">curecmd.org</ext-link>.</p>
          <p>Therapies currently under investigation target apoptosis with drugs such as omigapil [<xref ref-type="bibr" rid="mdef-cmd.REF.erb.2009.787">Erb et al 2009</xref>] and doxycycline [<xref ref-type="bibr" rid="mdef-cmd.REF.girgenrath.2009.47">Girgenrath et al 2009</xref>], and genetic manipulation of BAX [<xref ref-type="bibr" rid="mdef-cmd.REF.girgenrath.2004.1635">Girgenrath et al 2004</xref>]. Additional approaches include protein replacement therapy using miniagrin constructs and pro-regenerative approaches using IgF [<xref ref-type="bibr" rid="mdef-cmd.REF.kumar.2011.2333">Kumar et al 2011</xref>].</p>
          <p>Another approach for the treatment of genetic disorders caused by premature termination codons is the use of drugs to force stop codon read-through [<xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2008.217">Allamand et al 2008</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="mdef-cmd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="mdef-cmd.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">LAMA2</italic>-related muscular dystrophy (<italic toggle="yes">LAMA2</italic> MD) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="mdef-cmd.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutated allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with <italic toggle="yes">LAMA2</italic> MD are obligate heterozygotes (carriers) for a pathogenic <italic toggle="yes">LAMA2</italic> variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="mdef-cmd.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="mdef-cmd.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="mdef-cmd.Prenatal_Testing_and_Preimplant">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">LAMA2</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p><bold>Linkage and immunohistochemistry.</bold> When two <italic toggle="yes">LAMA2</italic> pathogenic variants are not identified in the family, linkage analysis and evaluation of laminin &#x003b1;2 by immunohistochemical (IHC) staining in chorionic villi may be available in certain specialized laboratories [<xref ref-type="bibr" rid="mdef-cmd.REF.vainzof.2005.588">Vainzof et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="mdef-cmd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="mdef-cmd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="mdef-cmd.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The phenotype of <italic toggle="yes">LAMA2</italic> MD is caused by deficiency in the basal lamina of muscle fibers of the &#x003b1;2 chain of laminins 2 and 4 (encoded by <italic toggle="yes">LAMA2</italic>). Hypotheses regarding the pathogenesis of <italic toggle="yes">LAMA2</italic> MD resulting in congenital muscular dystrophy include: disruption of cellular signaling; disruption of nerve-muscle interaction leading to denervation atrophy; and mechanical instability. The most likely hypothesis from studies with zebrafish is one of mechanical instability of the sarcolemma resulting in cellular damage and subsequent apoptosis [<xref ref-type="bibr" rid="mdef-cmd.REF.hall.2007.7092">Hall et al 2007</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">LAMA2</italic> spans 260 kb and the longest transcript variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000426.3">NM_000426.3</ext-link>) has 65 exons and a very large mRNA of 9.5 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mdef-cmd" object-id="mdef-cmd.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> The majority of pathogenic alleles are missense, nonsense, or splicing variants and small deletions, insertions, or duplications within exons that are readily detected by sequence analysis of the coding and associated flanking intronic regions. To date, 94 distinct pathogenic variants distributed throughout the gene have been reported in the <italic toggle="yes">LAMA2</italic> locus-specific database (<related-object source-id="gene" document-id="mdef-cmd" object-id="mdef-cmd.molgen.TA">Table A</related-object>), the majority of which are small out-of-frame deletions (31.9%) and nonsense variants (29.8%). Others include splice variants (16.0%), missense substitutions (14.9%), and small duplications (7.4%) [<xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>].</p>
          <p>Commonly reported pathogenic variants (exact prevalence in early-onset <italic toggle="yes">LAMA2</italic> MD population unknown) included in <xref ref-type="table" rid="mdef-cmd.T.selected_lama2_pathogenic_var">Table 2</xref> are c.2901C&#x0003e;A, c.1854_1861dup, c.2048-2049del, c.7750-1713_78899-2153del4987 (deletion of exon 56), and c.7881T&#x0003e;G.</p>
          <p>Commonly reported pathogenic variants (<xref ref-type="table" rid="mdef-cmd.T.summary_of_molecular_genetic">Table 1</xref> and <xref ref-type="table" rid="mdef-cmd.T.selected_lama2_pathogenic_var">Table 2</xref>) include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>A nonsense variant c.2901C&#x0003e;A that confers a phenotype ranging from sitting unsupported to ambulation with assistance depending on the type of variant in the second allele. c.2901C&#x0003e;A is reported as an Italian founder variant [<xref ref-type="bibr" rid="mdef-cmd.REF.guicheney.1998.211">Guicheney et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.di_blasi.2005.1582">Di Blasi et al 2005</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.vigliano.2009.72">Vigliano et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>The duplication c.1854_1861dup, associated with a phenotype ranging from sitting unsupported to spastic gait [<xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p>A 2-bp deletion, c.2048_2049del, associated with the ability to sit unsupported [<xref ref-type="bibr" rid="mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al 1998</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</xref>, <xref ref-type="bibr" rid="mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</xref>]</p>
            </list-item>
            <list-item>
              <p>A deletion of ~5 kb (c.7750-1713_78899-2153del4987), identified in 31% of affected individuals (N = 52 alleles). An allele-specific PCR test was developed [<xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>A homozygous Kenyan founder variant, c.7881T&#x0003e;G, associated with a variable clinical phenotype [<xref ref-type="bibr" rid="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</xref>]</p>
            </list-item>
          </list>
          <table-wrap id="mdef-cmd.T.selected_lama2_pathogenic_var" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">LAMA2</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2049_2050del<break/>(2048_2049del)</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg683SerfsTer21</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000426.3">NM_000426.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000417.2">NP_000417.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2901C&#x0003e;A</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys976Ter</td>
                </tr>
                <tr>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1854_1861dup</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu621HisfsTer7</td>
                </tr>
                <tr>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.7881T&#x0003e;G</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His2627Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.7750-1713_78899-2153del4987&#x000a0;<sup>2</sup><break/>(~5 kb deletion)</td>
                  <td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala2584HisfsTer8</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="mdef-cmd.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="mdef-cmd.TF.2.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="mdef-cmd.REF.oliveira.2008.502">Oliveira et al [2008]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> Laminins are a group of heterotrimeric glycoproteins composed of a heavy &#x003b1; chain and two light chains, &#x003b2; and &#x003b3;, each of which is encoded by a separate gene. To date, five &#x003b1; chains (designated &#x003b1;1 to &#x003b1;5), four &#x003b2; chains (&#x003b2;1 to &#x003b2;3), and three &#x003b3; chains (&#x003b3;1 to &#x003b3;3) have been identified, which combine to form 15 laminin isoforms, each with tissue and/or developmental stage-specific expression [<xref ref-type="bibr" rid="mdef-cmd.REF.suzuki.2005.142">Suzuki et al 2005</xref>]. In skeletal muscle, the predominant isoforms are laminin &#x003b1;2 (also known as merosin), which is composed of &#x003b1;2, &#x003b1;1, and &#x003b3;1 chains and laminin-4, composed of &#x003b1;2, &#x003b2;2, and &#x003b3;1 chains. Laminins are secreted into the extracellular matrix where they bind to neurexin, agrin, and collagen IV in the extracellular matrix and to dystroglycan and integrins in the sarcolemmal membrane [<xref ref-type="bibr" rid="mdef-cmd.REF.muntoni.2004.635">Muntoni &#x00026; Voit 2004</xref>]. The biologic functions of laminins are varied and include cell-cell recognition, growth, differentiation, cell shape, and migration [<xref ref-type="bibr" rid="mdef-cmd.REF.suzuki.2005.142">Suzuki et al 2005</xref>].</p>
          <p><italic toggle="yes">LAMA2</italic> encodes a 400-kd protein that is post-translationally cleaved into 300-kd and 80-kd subunits, which remain associated by disulfide bonds. Laminin &#x003b1;2 is expressed in the striated muscle basement membrane, the cerebral blood vessels including the capillaries that form the blood-brain barrier, the glia limitans, the developing axon tracts, and Schwann cells.</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic loss-of-function variants in <italic toggle="yes">LAMA2</italic> typically lead to early-onset <italic toggle="yes">LAMA2</italic> MD.</p>
        </sec>
      </sec>
      <sec id="mdef-cmd.References">
        <title>References</title>
        <sec id="mdef-cmd.Published_GuidelinesConsensus_S">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="mdef-cmd.Published_GuidelinesConsensus_S.reflist0">
            <ref id="mdef-cmd.REF.wang.2010">
              <mixed-citation publication-type="web">Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, B&#x000e9;roud C, Bertini E, Bushby K,Cohn D, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R. Consensus statement on standard of care for congenital muscular dystrophies. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jcn.sagepub.com/content/25/12/1559.long">online</ext-link>. 2010. Accessed 3-22-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="mdef-cmd.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="mdef-cmd.Literature_Cited.reflist0">
            <ref id="mdef-cmd.REF.alkan.2007.655">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alkan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sigirci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutlu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aslan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doganay</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yakinci</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Merosin-negative congenital muscular dystrophy: diffusion-weighted imaging findings of brain.</article-title>
                <source>J Child Neurol.</source>
                <volume>22</volume>
                <fpage>655</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17690079</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.allamand.2008.217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allamand</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bidou</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arakawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Floquet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiozuka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paturneau-Jouas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gartioux</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler-Browne</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rousset</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes.</article-title>
                <source>J Gene Med.</source>
                <volume>10</volume>
                <fpage>217</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">18074402</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.allamand.2002.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allamand</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, <italic toggle="yes">LAMA2</italic> gene coding for alpha2 chain of laminin).</article-title>
                <source>Eur J Hum Genet.</source>
                <volume>10</volume>
                <fpage>91</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11938437</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.aslan.2005.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aslan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yakinci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonmezgoz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bicak</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorludemir</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Merosin-negative Congenital muscular dystrophy: magnetic resonance spectroscopy findings.</article-title>
                <source>Brain Dev.</source>
                <volume>27</volume>
                <fpage>308</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">15862197</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.bentley.2001.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bentley</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bull</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seingry</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The treatment of scoliosis in muscular dystrophy using modified Luque and Harrington-Luque instrumentation.</article-title>
                <source>J Bone Joint Surg Br.</source>
                <volume>83</volume>
                <fpage>22</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11245532</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.carboni.2011.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carboni</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marrosu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mateddu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cocco</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maioli</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piras</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marrosu</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin-&#x003b1;2-chain gene: a chance association or a novel phenotype?</article-title>
                <source>Muscle Nerve.</source>
                <volume>44</volume>
                <fpage>826</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22006699</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.darin.2000.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Darin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tulinius</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>10</volume>
                <fpage>1</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10677857</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.di_blasi.2005.1582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Blasi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piga</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brioschi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moroni</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruggieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanotti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uziel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarre</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Giustina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scuderi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonsrud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mantegazza</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morandi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title><italic toggle="yes">LAMA2</italic> gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect.</article-title>
                <source>Arch Neurol.</source>
                <volume>62</volume>
                <fpage>1582</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16216942</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.di_muzio.2003.500">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Muzio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Angelis</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Fulvio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pizzuti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuppia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uncini</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy.</article-title>
                <source>Muscle Nerve.</source>
                <volume>27</volume>
                <fpage>500</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12661054</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.erb.2009.787">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erb</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barzaghi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumanovski</surname>
                    <given-names>LT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Courdier-Fr&#x000fc;h</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000fc;egg</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meier</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency.</article-title>
                <source>J Pharmacol Exp Ther.</source>
                <volume>331</volume>
                <fpage>787</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">19759319</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.geranmayeh.2010.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Geranmayeh</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clement</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feng</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brueton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>A-M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Goede</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>J-P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chow</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sousa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Mahony</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majumdar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlation in a large population of muscular dystrophy patients with <italic toggle="yes">LAMA2</italic> mutations.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2010</year>
                <volume>20</volume>
                <fpage>241</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">20207543</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.gilhuis.2002.30">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gilhuis</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ten Donkelaar</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanke</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vingerhoets</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwarts</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verrips</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabre&#x000eb;ls</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Nonmuscular involvement in merosin-negative congenital muscular dystrophy.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>26</volume>
                <fpage>30</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11814732</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.girgenrath.2009.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Girgenrath</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beermann</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vishnudas</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Homma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>JB</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.</article-title>
                <source>Ann Neurol.</source>
                <volume>65</volume>
                <fpage>47</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">19086074</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.girgenrath.2004.1635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Girgenrath</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dominov</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kostek</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>JB</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.</article-title>
                <source>J Clin Invest.</source>
                <volume>114</volume>
                <fpage>1635</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15578095</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.gu_rin.2010.866">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gu&#x000e9;rin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petitjean</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecam</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luizet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabilloud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The short-term effects of intermittent positive pressure breathing treatments on ventilation in patients with neuromuscular disease.</article-title>
                <source>Respir Care.</source>
                <volume>55</volume>
                <fpage>866</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20587098</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.guicheney.1998.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vignier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frey</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helbling-Leclerc</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topaloglu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harpey</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haenggeli</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainque</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tryggvason</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>PCR based mutation screening of the laminin alpha2 chain gene (<italic toggle="yes">LAMA2</italic>): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy.</article-title>
                <source>J Med Genet.</source>
                <volume>35</volume>
                <fpage>211</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9541105</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.hall.2007.7092">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryson-Richardson</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacoby</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollway</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Currie</surname>
                    <given-names>PD</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>104</volume>
                <fpage>7092</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17438294</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.hara.2011.939">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balci-Hayta</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida-Moriguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanagawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beltr&#x000e1;n-Valero de Bernab&#x000e9;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;nde&#x0015f;li</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satz</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burden</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldstone</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Accardi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talim</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topalo&#x0011f;lu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Din&#x000e7;er</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A dystroglycan mutation associated with limb-girdle muscular dystrophy.</article-title>
                <source>N Engl J Med.</source>
                <volume>364</volume>
                <fpage>939</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">21388311</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.hayashi.2001.350">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tezak</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Momoi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonaka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arahata</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>11</volume>
                <fpage>350</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11369186</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.he.2001.1319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vignier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevallay</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet-Mathiaud</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hori</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>KN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Congenital muscular dystrophy with primary partial laminin alpha2 chain deficiency: molecular study.</article-title>
                <source>Neurology.</source>
                <volume>57</volume>
                <fpage>1319</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">11591858</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.jones.2001.649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tobias</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouvrier</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilkinson</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>KN</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.</article-title>
                <source>J Med Genet.</source>
                <volume>38</volume>
                <fpage>649</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">11584042</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.jones.2012.e141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waite</surname>
                    <given-names>PD</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Orthognathic surgery and partial glossectomy in a patient with merosin-deficient congenital muscular dystrophy.</article-title>
                <source>J Oral Maxillofac Surg.</source>
                <volume>70</volume>
                <fpage>e141</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22260916</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.kumar.2011.2333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamauchi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girgenrath</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girgenrath</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Muscle-specific expression of insulin-like growth factor 1 improves outcome in <italic toggle="yes">LAMA2</italic> Dy-w mice, a model for congenital muscular dystrophy type 1A.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>20</volume>
                <fpage>2333</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">21441569</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.leite.2005.190">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leite</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reed</surname>
                    <given-names>UC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otaduy</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacerda</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resende</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marie</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerri</surname>
                    <given-names>GG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Congenital muscular dystrophy with merosin deficiency: 1H MR spectroscopy and diffusion-weighted MR imaging.</article-title>
                <source>Radiology.</source>
                <volume>235</volume>
                <fpage>190</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15703311</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.mellies.2005.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mellies</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dohna-Schwake</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Respiratory function assessment and intervention in neuromuscular disorders.</article-title>
                <source>Curr Opin Neurol.</source>
                <volume>18</volume>
                <fpage>543</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16155437</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.mellies.2003.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mellies</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ragette</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwake</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boehm</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teschler</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular disorders.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>13</volume>
                <fpage>123</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12565909</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.mercuri.1998.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philpot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Visual function in children with merosin-deficient and merosin-positive congenital muscular dystrophy.</article-title>
                <source>Pediatr Neurol.</source>
                <volume>18</volume>
                <fpage>399</fpage>
                <lpage>401</lpage>
                <pub-id pub-id-type="pmid">9650678</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.mercuri.2001.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutherford</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vile</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Counsell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bydder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Early white matter changes on brain magnetic resonance imaging in a newborn affected by merosin-deficient congenital muscular dystrophy.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>11</volume>
                <fpage>297</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11297945</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.messina.2010.898">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Messina</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moroni</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pegoraro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biancheri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berardinelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boffi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassandrini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farina</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mongini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mottarelli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pane</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pantaleoni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pichiecchio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saredi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sframeli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortorella</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisan</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uggetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasco</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Congenital muscular dystrophies with cognitive impairment. A population study.</article-title>
                <source>Neurology</source>
                <volume>75</volume>
                <fpage>898</fpage>
                <lpage>903</lpage>
                <pub-id pub-id-type="pmid">20820001</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.mostacciuolo.1996.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mostacciuolo</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miorin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinello</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisan</surname>
                    <given-names>CP</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Genetic epidemiology of congenital muscular dystrophy in a sample from north east Italy.</article-title>
                <source>Hum Genet</source>
                <volume>97</volume>
                <fpage>277</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8786062</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.muntoni.2004.635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The congenital muscular dystrophies in 2004: a century of exciting progress.</article-title>
                <source>Neuromusc. Disord.</source>
                <volume>14</volume>
                <fpage>635</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">15351421</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.naom.1998.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naom</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Alessandro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philpot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Laminin alpha 2-chain gene mutations in two siblings presenting with limb-girdle muscular dystrophy.</article-title>
                <source>Neuromusc Disord</source>
                <volume>8</volume>
                <fpage>495</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">9829280</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.oliveira.2008.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soares-Silva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorge</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieira</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coelho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbosa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prats</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ar&#x000ed;ztegui</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinimann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pascual-Pascual</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabral</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fineza</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bronze-da-Rocha</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title><italic toggle="yes">LAMA2</italic> gene analysis in a cohort of 26 congenital muscular dystrophy patients.</article-title>
                <source>Clin Genet.</source>
                <volume>74</volume>
                <fpage>502</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">18700894</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.pegoraro.1998.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pegoraro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancias</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinello</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisan</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scavina</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munk</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;nnemann</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertorini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acsadi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnon</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoganson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carver</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmerman</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>EP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients.</article-title>
                <source>Neurology.</source>
                <volume>51</volume>
                <fpage>101</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">9674786</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.philpot.1999a.542">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Philpot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bagnall</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1999a</year>
                <article-title>Feeding problems in merosin deficient congenital muscular dystrophy.</article-title>
                <source>Arch Dis Child</source>
                <volume>80</volume>
                <fpage>542</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10332004</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.philpot.1999b.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Philpot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennock</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bydder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1999b</year>
                <article-title>Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>9</volume>
                <fpage>81</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10220862</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.pini.1996.316">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevallay</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobbi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families.</article-title>
                <source>Brain Dev.</source>
                <volume>18</volume>
                <fpage>316</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">8879653</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.quijanoroy.2004.292">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renault</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>EMG and nerve conduction studies in children with congenital muscular dystrophy.</article-title>
                <source>Muscle Nerve</source>
                <volume>29</volume>
                <fpage>292</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14755496</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.rajakulendran.2011.590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rajakulendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holton</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical and pathological heterogeneity in late-onset partial merosin deficiency.</article-title>
                <source>Muscle Nerve.</source>
                <volume>44</volume>
                <fpage>590</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">21922472</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.sewry.1997.169">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naom</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Alessandro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorokin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubowitz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>7</volume>
                <fpage>169</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">9185180</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.siala.2007.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Siala</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Louhichi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Triki</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morini&#x000e8;re</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baklouti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fakhfakh</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Severe MDC1A congenital muscular dystrophy due to a splicing mutation in the LAMA2 gene resulting in exon skipping and significant decrease of mRNA level.</article-title>
                <source>Genet Test.</source>
                <year>2007</year>
                <volume>11</volume>
                <fpage>199</fpage>
                <lpage>207</lpage>
                <pub-id pub-id-type="pmid">17949279</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.spyrou.1998.474">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spyrou</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philpot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foale</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camici</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy.</article-title>
                <source>Am Heart J.</source>
                <volume>136</volume>
                <fpage>474</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9736139</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.sunada.1995.2084">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sunada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edgar</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lotz</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rust</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities.</article-title>
                <source>Neurology.</source>
                <volume>45</volume>
                <fpage>2084</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7501163</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.suzuki.2005.142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokoyama</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomizu</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Functional sites in the laminin alpha chains.</article-title>
                <source>Connect. Tissue Res.</source>
                <volume>46</volume>
                <fpage>142</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16147852</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.tezak.2003.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tezak</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prandini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boscaro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devaney</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisan</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finkel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pegoraro</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (<italic toggle="yes">LAMA2</italic>) deficiency.</article-title>
                <source>Hum Mutat.</source>
                <volume>21</volume>
                <fpage>103</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">12552556</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.vainzof.2005.588">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vainzof</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jimenez-Mallebrera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talim</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>LU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledeuil</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brockington</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zatz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topaloglu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five international centers.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>15</volume>
                <fpage>588</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">16084089</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.vigliano.2009.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vigliano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dassi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Blasi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarre</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title><italic toggle="yes">LAMA2</italic> stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression.</article-title>
                <source>Eur J Paediatr Neurol.</source>
                <volume>13</volume>
                <fpage>72</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18406646</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.wallgrenpettersson.2004.56">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallgren-Pettersson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellies</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonds</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>117th ENMC workshop: ventilatory support in congenital neuromuscular disorders -- congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>14</volume>
                <fpage>56</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">14659414</pub-id>
              </element-citation>
            </ref>
            <ref id="mdef-cmd.REF.wang.2010.1559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutkowski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sejersen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellini</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battista</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florence</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schara</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuler</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahbi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aloysius</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bash</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;roud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohn</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deconinck</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet-Mathiaud</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouinot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Main</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melacini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahbek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storhaug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonds</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tseng</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vajsar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeller</surname>
                    <given-names>R</given-names>
                  </name>
                  <collab>International Standard of Care Committee for Congenital Muscular Dystrophy</collab>
                </person-group>
                <year>2010</year>
                <article-title>Consensus statement on standard of care for congenital muscular dystrophies.</article-title>
                <source>J Child Neurol.</source>
                <volume>25</volume>
                <fpage>1559</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">21078917</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="mdef-cmd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="mdef-cmd.Author_Notes">
          <title>Author Notes</title>
          <p>Susan Sparks, MD, PhD is a board-certified pediatrician with additional board certifications in Clinical Genetics and Clinical Biochemical Genetics. At the Children&#x02019;s National Medical Center (CNMC) in Washington, DC under the direction of Dr Eric Hoffman at CNMC, Dr Sparks was awarded a Wellstone fellowship to do research in the clinical, molecular, and biochemical characterization of muscular dystrophies caused by a defect in O-linked glycan synthesis, a group known as the dystroglycanopathies. The dystroglycanopathies range clinically from congenital onset of muscular dystrophy with CNS and eye involvement, to a later onset form of limb-girdle muscular dystrophy (LGMD), without any CNS or eye involvement. Dr Sparks is also involved in the clinical characterization and evaluation of congenital muscular dystrophies and limb-girdle muscular dystrophies and has experience in preclinical and clinical trials in Duchenne muscular dystrophy. She is currently a medical director for genetic diseases with Genzyme, a Sanofi company.</p>
          <p>Anne Rutkowski is chairman of Cure CMD, a nonprofit advocating for CMD awareness and treatment. Cure CMD is an all-volunteer organization that has led the path to building infrastructure to enable clinical trials, including the CMD International Registry (CMDIR) and CMD Care Guidelines. To get to clinical trials requires genetic confirmation and localization of the global CMD population. For more information, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.curecmd.org">www.curecmd.org</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cmdir.org/">www.cmdir.org</ext-link>.</p>
        </sec>
        <sec id="mdef-cmd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>7 June 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>16 March 2010 (ss) Initial submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
